Celivarone

Drug Profile

Celivarone

Alternative Names: SSR 149744; SSR 149744B; SSR 149744C

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Antiarrhythmics; Benzofurans
  • Mechanism of Action Ion channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Supraventricular arrhythmias; Ventricular arrhythmias

Most Recent Events

  • 31 Dec 2011 Discontinued - Phase-II for Ventricular arrhythmias in Argentina (PO) during 2011
  • 31 Dec 2011 Discontinued - Phase-II for Ventricular arrhythmias in Australia (PO) during 2011
  • 31 Dec 2011 Discontinued - Phase-II for Ventricular arrhythmias in Belgium (PO) during 2011
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top